The U.S. peripheral liquid embolic agents market size was valued at USD 99.7 million in 2025 and is projected to grow from USD 110.3 million in 2026 to USD 222.7 million by 2036, at a CAGR of 7.3% from 2026 to 2036. The rising prevalence of peripheral artery disease (PAD) and other vascular disorders in the U.S. is increasing demand for vascular interventions.
In addition, minimally invasive endovascular procedures are gaining adoption due to reduced surgical trauma, shorter hospital stays, and faster recovery. The growing availability of interventional radiology services and advanced catheter-based techniques is further supporting the use of liquid embolic agents in peripheral vascular procedures. The growing cancer burden in the U.S. is increasing the number of patients requiring peripheral vascular embolization for the management of hypervascular tumors, particularly in interventional oncology. Procedures such as transarterial embolization (TAE) and transarterial chemoembolization (TACE) selectively occlude tumor-feeding vessels, creating a demand for embolic technologies capable of controlled, targeted vessel occlusion.
Liquid embolic agents are particularly relevant because they can penetrate distal and complex vascular networks and form an occlusive cast within the targeted vessels. The increasing use of image-guided embolization for liver and other hypervascular tumors, together with advances in microcatheter delivery and embolic technology, is expanding the range of applications for peripheral liquid embolics. In the U.S., embolization therapies accounted for a substantial share of the interventional oncology procedures market, with liver cancer the largest cancer-type segment in 2025. According to the American Cancer Society, 42,240 new cases of primary liver and intrahepatic bile duct cancer were expected in the U.S. in 2025, with approximately 30,090 deaths, highlighting the substantial patient population requiring effective treatment options, including transarterial embolization.
In addition, minimally invasive endovascular procedures are gaining adoption due to reduced surgical trauma, shorter hospital stays, and faster recovery. The growing availability of interventional radiology services and advanced catheter-based techniques is further supporting the use of liquid embolic agents in peripheral vascular procedures. The growing cancer burden in the U.S. is increasing the number of patients requiring peripheral vascular embolization for the management of hypervascular tumors, particularly in interventional oncology. Procedures such as transarterial embolization (TAE) and transarterial chemoembolization (TACE) selectively occlude tumor-feeding vessels, creating a demand for embolic technologies capable of controlled, targeted vessel occlusion.
Liquid embolic agents are particularly relevant because they can penetrate distal and complex vascular networks and form an occlusive cast within the targeted vessels. The increasing use of image-guided embolization for liver and other hypervascular tumors, together with advances in microcatheter delivery and embolic technology, is expanding the range of applications for peripheral liquid embolics. In the U.S., embolization therapies accounted for a substantial share of the interventional oncology procedures market, with liver cancer the largest cancer-type segment in 2025. According to the American Cancer Society, 42,240 new cases of primary liver and intrahepatic bile duct cancer were expected in the U.S. in 2025, with approximately 30,090 deaths, highlighting the substantial patient population requiring effective treatment options, including transarterial embolization.
U.S. Peripheral Liquid Embolic Agents Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2036. For this study, the analyst has segmented the U.S. peripheral liquid embolic agents market report based on product, application, and end-use:Product Outlook (Revenue, USD Million, 2021 - 2036)
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- Others
Application Outlook (Revenue, USD Million, 2021 - 2036)
- Peripheral Vascular Hemorrhage
- Hypervascular Tumors
- Peripheral Vascular Malformations / AVMs
- Aneurysms / Pseudoaneurysms
- Type II Endoleaks
- Portal Vein Embolization (PVE)
- Venous Applications (varicocele, PCS, varicose veins)
- Other Peripheral Embolization Applications
End-use Outlook (Revenue, USD Million, 2021 - 2036)
- Hospitals & Interventional Radiology (IR) Suites
- Ambulatory Surgical Centers (ASCs)
- Specialty Clinics / Vascular Centers
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Peripheral Liquid Embolic Agents Market Variables, Trends, & Scope
Chapter 4. U.S. Peripheral Liquid Embolic Agents Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Peripheral Liquid Embolic Agents Market: Application Estimates & Trend Analysis
Chapter 6. U.S. Peripheral Liquid Embolic Agents Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Boston Scientific Corporation
- Terumo Medical Corporation (MicroVention)
- BlackSwan Vascular (Sirtex Medical)
- Instylla, Inc.
